Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast — Oct 17th, 2024

Intra-Cellular Therapies Inc. NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a...

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast — Oct 17th, 2024

Intra-Cellular Therapies Inc. NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a...

Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds — Oct 13th, 2024

We recently compiled a list of the 10 Most Promising Mid-Cap Stocks According to Hedge Funds.In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against the other promising mid-cap stocks. The S&P 500 May Hit 6,000 in 2024 September c...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds — Oct 13th, 2024

We recently compiled a list of the 10 Most Promising Mid-Cap Stocks According to Hedge Funds.In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against the other promising mid-cap stocks. The S&P 500 May Hit 6,000 in 2024 September c...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds — Oct 13th, 2024

We recently compiled a list of the 10 Most Promising Mid-Cap Stocks According to Hedge Funds.In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against the other promising mid-cap stocks. The S&P 500 May Hit 6,000 in 2024 September c...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds — Oct 13th, 2024

We recently compiled a list of the 10 Most Promising Mid-Cap Stocks According to Hedge Funds.In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against the other promising mid-cap stocks. The S&P 500 May Hit 6,000 in 2024 September c...

Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds — Oct 13th, 2024

We recently compiled a list of the 10 Most Promising Mid-Cap Stocks According to Hedge Funds.In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against the other promising mid-cap stocks. The S&P 500 May Hit 6,000 in 2024 September c...

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast — Oct 17th, 2024

Intra-Cellular Therapies Inc. NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a...

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast — Oct 17th, 2024

Intra-Cellular Therapies Inc. NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a...

Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds — Oct 13th, 2024

We recently compiled a list of the 10 Most Promising Mid-Cap Stocks According to Hedge Funds.In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against the other promising mid-cap stocks. The S&P 500 May Hit 6,000 in 2024 September c...

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast — Oct 17th, 2024

Intra-Cellular Therapies Inc. NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast — Oct 17th, 2024

Intra-Cellular Therapies Inc. NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds — Oct 13th, 2024

We recently compiled a list of the 10 Most Promising Mid-Cap Stocks According to Hedge Funds.In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against the other promising mid-cap stocks. The S&P 500 May Hit 6,000 in 2024 September c...

Intra-Cellular's Caplyta Sales Boost Revenues, Dependence a Woe — Oct 11th, 2024

Intra-Cellular ITCI is focused on discovering, developing and commercializing small molecule drugs for treating neuropsychiatric and neurological disorders. The company currently has only one marketed drug in its portfolio, Caplyta (lumateperone 42 mg). Caplyta – ITCI’s Key Growth Dri...

Intra-Cellular Therapies, Inc. (ITCI): Among the Most Promising Mid-Cap Stocks According to Hedge Funds — Oct 13th, 2024

We recently compiled a list of the 10 Most Promising Mid-Cap Stocks According to Hedge Funds.In this article, we are going to take a look at where Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) stands against the other promising mid-cap stocks. The S&P 500 May Hit 6,000 in 2024 September c...

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast — Oct 17th, 2024

Intra-Cellular Therapies Inc. NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a...

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast — Oct 17th, 2024

Intra-Cellular Therapies Inc. NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a...

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress — Sep 23rd, 2024

Intra-Cellular Therapies Inc. Oral and poster presentations of results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) Poster presentations of post-hoc analyses from Study 403 including the pres...

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast — Oct 17th, 2024

Intra-Cellular Therapies Inc. NEW YORK, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a...